Beyond The Numbers: 4 Analysts Discuss Beta Bionics Stock

Analysts' ratings for Beta Bionics (NASDAQ:BBNX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 1 0 0 Last 30D 0 0 1 0 0 1M Ago 2 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Beta Bionics, revealing an average target of $31.75, a high estimate of $40.00, and a low estimate of $17.00. This current average represents a 1.79% decrease from the previous average price target of $32.33. Decoding Analyst Ratings: A Detailed Look A comprehensive examination of how financial experts perceive Beta Bionics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mathew Blackman TD Cowen Announces Hold $17.00 - Frank Takkinen Lake Street Raises Buy $40.00 $35.00 Travis Steed B of A Securities Raises Buy $33.00 $30.00 Richard Newitter Truist Securities Raises Buy $37.00 $32.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beta Bionics. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Beta Bionics compared to the broader market. Price Targets: Gaining insights, analysts provide estimates for the future value of Beta Bionics's stock. This comparison reveals trends in analysts' expectations over time. Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Beta Bionics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table. Stay up to date on Beta Bionics analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here. Get to Know Beta Bionics Better Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet. Financial Milestones: Beta Bionics's Journey Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity. Revenue Growth: Beta Bionics's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 63.14%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. Net Margin: Beta Bionics's net margin is impressive, surpassing industry averages. With a net margin of -52.14%, the company demonstrates strong profitability and effective cost management. Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -4.76%, the company showcases effective utilization of equity capital. Return on Assets (ROA): Beta Bionics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.31%, the company demonstrates effective utilization of assets and strong financial performance. Debt Management: With a below-average debt-to-equity ratio of 0.03, Beta Bionics adopts a prudent financial strategy, indicating a balanced approach to debt management. How Are Analyst Ratings Determined? Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions. Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors. This article was generated by Benzinga's automated content engine and reviewed by an editor.